Butyrate producers as potential next-generation probiotics : safety assessment of the administration of Butyricicoccus pullicaecorum to healthy volunteers by Boesmans, Leen et al.
Butyrate Producers as Potential Next-Generation Probiotics:
Safety Assessment of the Administration of Butyricicoccus
pullicaecorum to Healthy Volunteers
Leen Boesmans,a Mireia Valles-Colomer,b,c Jun Wang,b,c Venessa Eeckhaut,d Gwen Falony,b,c Richard Ducatelle,d
Filip Van Immerseel,d Jeroen Raes,b,c,e Kristin Verbekea,f
aTranslational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
bLaboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KU
Leuven, Leuven, Belgium
cCenter for Microbiology, VIB, Leuven, Belgium
dDepartment of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University,
Merelbeke, Belgium
eResearch Group of Microbiology, Department of Bioengineering Sciences, Vrije Universiteit Brussel, Brussels,
Belgium
fLeuven Food Science and Nutrition Research Center, KU Leuven, Leuven, Belgium
ABSTRACT Advances in gut microbiota research have triggered interest in develop-
ing colon butyrate producers as niche-speciﬁc next-generation probiotics, targeted
at increasing colon butyrate production and countering disease-associated microbi-
ota alterations. Crucial steps in the development of next-generation probiotics are
the design of formulations with a reasonable shelf life as well as the safety demon-
stration of an intervention in healthy volunteers. One such potential next-generation
butyrate-producing probiotic is Butyricicoccus pullicaecorum 25-3T, with demon-
strated safety in in vitro as well as animal models. Here, we examined the strain’s
safety, tolerability, and impact on microbiota composition and metabolic activity in
healthy volunteers in a randomized, double-blind, placebo-controlled crossover study in
30 healthy volunteers. The study design consisted of two 4-week intervention peri-
ods (108 CFU B. pullicaecorum [treatment] or maltodextrin [placebo] per day) with a
3-week washout in between. We assessed adverse events, blood parameters (pri-
mary endpoints), and fecal microbiota composition and metabolite proﬁles (second-
ary endpoints). The number of reported adverse events during the B. pullicaecorum
treatment was similar to that of placebo intervention, as were observed changes in
blood chemistry parameters, bowel habits, and fecal calprotectin concentrations. Ad-
ministration of the strain did not induce any disruptive effect in microbiota composi-
tion or metabolic activity. In this ﬁrst human intervention trial with a butyrate-
producing Clostridium cluster IV isolate, we demonstrated B. pullicaecorum 25-3T
administration to be both safe and well tolerated by healthy participants. This safety
study paves the way for the further development of the strain as a next-generation
probiotic.
IMPORTANCE This study is the ﬁrst to determine the safety and tolerance in hu-
mans of a butyrate-producing Clostridium cluster IV next-generation probiotic. Ad-
vances in gut microbiota research have triggered interest in developing colon bu-
tyrate producers as next-generation probiotics. Butyricicoccus pullicaecorum 25-3T is
one such potential probiotic, with demonstrated safety in vitro as well as in animal
models. Here, we produced an encapsulated B. pullicaecorum formulation that
largely preserved its viability over an 8-month storage period at 4°C. Administration
of this formulation to healthy volunteers allowed us to establish the intervention as
safe and well tolerated. The probiotic intervention did not cause disruptive altera-
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tions in the composition or metabolic activity of health-associated microbiota. The
results presented pave the way for the exploration of the impact of the strain on
microbiota alterations in a clinical setting.
KEYWORDS Butyricicoccus pullicaecorum, metabolome, microbiome, next-generation
probiotic, safety, tolerance
Due to its close association with host health, the human gut microbiota is widelyconsidered a promising target for preventive and therapeutic interventions (1–3).
Based on the assumption of a causal or cocausal implication of microbiota alterations
in the development or persistence of suboptimal health or disease conditions, several
approaches to modulate the composition or metabolic activity of the gut microbial
community have been proposed (4). Such microbiota modulation strategies aim at
restoring ecosystem eubiosis by introducing or promoting growth of beneﬁcial bacteria
or bacterial consortia (5, 6). Ultimately, even the replacement of a dysbiotic bacterial
community by a health-associated microbiota through fecal transplantation can be
envisaged (7).
A long-standing microbiota modulation approach is the use of probiotics, live
microorganisms that, when administered in adequate amounts, confer a health beneﬁt
on the host (6). For many years, probiotic research has mainly—although not exclu-
sively (8, 9)—revolved around biﬁdobacteria and lactic acid bacteria (6). Lately, how-
ever, following up on new insight into the interactions between the gut microbiota and
the human host, a whole new range of gut isolates have drawn the attention of the
probiotic community (10). Such next-generation probiotics are rather broadly deﬁned
as probiotics that have not been used as agents to promote health to date (10). A
particularly interesting category of such potential next-generation probiotics comprises
Clostridium cluster IV/XIVa colon butyrate producers (11). The rationale underlying this
interest is straightforward: butyrate is the major energy source for colonocytes, inﬂu-
ences cell differentiation, and strengthens the epithelial defense barrier (12, 13).
Notwithstanding some noteworthy exceptions (14), butyrate has repeatedly been
shown to reduce intestinal inﬂammation (13), as reﬂected in the decreased abundance
of butyrate producers in feces of inﬂammatory bowel disease (IBD) patients (15, 16).
Hence, the administration of colon butyrate producers could become an essential part
of IBD management by counteracting dysbiosis and promoting overall gut health (17).
Isolated from the cecum of broiler chickens (18), Butyricicoccus pullicaecorum 25-3T
is a Gram-positive, strictly anaerobic Clostridium cluster IV bacterium that produces high
levels of butyrate (18). Following up on its observed reduced relative abundance in
fecal samples of IBD patients (19), the safety and probiotic potential of the strain have
been assessed throughout a series of in vitro and animal experiments. Whole-genome
sequencing indicated B. pullicaecorum to be nonvirulent, with limited antibiotic resis-
tance potential (20). B. pullicaecorum safety has been demonstrated in rats through
both standard acute and 28-day repeated oral dose toxicity tests (20). The bacterium
was shown to be intrinsically tolerant to stomach and small intestine conditions (21).
Regarding its potential anti-inﬂammatory properties, B. pullicaecorum cell culture su-
pernatant enhanced barrier integrity in inﬂamed CaCo-2 epithelial cells (19). Overall, B.
pullicaecorum has gained the status of a promising exponent of the recent wave of
next-generation probiotics that are currently making their way into clinical practice.
Here, in line with the recommendations of World Health Organization (22), we
assessed the safety and tolerability of B. pullicaecorum in an exploratory phase 1 trial
(ClinicalTrials.gov identiﬁer NCT02477033). First, we up-scaled production of the strain
and designed a protocol allowing stable encapsulation. Next, we performed what is to
our knowledge the ﬁrst randomized, double-blind, placebo-controlled crossover trial in
healthy volunteers with a butyrate-producing Clostridium cluster IV bacterium. Evalu-
ation endpoints comprised the impact of B. pullicaecorum administration on subjects’
health, fecal microbiome composition, and stool metabolome proﬁles. The present
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study represents a crucial step in the ongoing exploration of the probiotic potential of
B. pullicaecorum.
RESULTS
A stable Butyricicoccus pullicaecorum formulation. Given the often strict anaer-
obic metabolism of the bacterial strains of interest (23), production and conservation
represent major challenges in the development of next-generation probiotic formula-
tions suited for human consumption. Here, we cultured B. pullicaecorum 25-3T under
anaerobic conditions, and the lyophilized culture was used to ﬁll hydroxypropyl meth-
ylcellulose (HPMC) capsules at a concentration of 108 CFU/capsule—the maximal dose
that ﬁt in the capsules. Sealed and coated capsules remained intact after 2 h in 0.1 M
HCl and disintegrated after 17 min at pH 6.8. Capsules were stored in aluminum sachets
at 4°C. Eight months after production (4 months after completion of the study),
bacterial viability was assessed as a measure for product stability. On average, capsules
were found to contain 6.7  107 CFU (67% viability), indicating an acceptable shelf life
of the probiotic formulation.
Administration of Butyricicoccus pullicaecorum is safe and well tolerated. To
evaluate safety of B. pullicaecorum administration, we set up a randomized, double-
blind, placebo-controlled crossover trial with healthy volunteers. Thirty healthy subjects
(16 female and 14 male; age, 22 to 52 years; body mass index [BMI], 18.9 to 27.8 kg/m2)
were recruited and randomized over two intervention sequences between February
and June 2014. Both groups were balanced according to gender, age, BMI, and smoking
habits (Table 1). In addition, no differences in medication intake were detected (chi-
square test [2]  0.14 and P 0.712, with intake of medication affecting intestinal
transit or gut microbiota among the exclusion criteria [Table 1]), and participants were
instructed to follow their usual diet throughout the study. The study setup covered a
1-week run-in and two 4-week intervention periods, each followed by a washout of 3
weeks (Fig. 1). Two subjects from one group dropped out of the study due to antibiotic
treatment during the ﬁrst intervention period and were excluded from further analyses.
Compliance rates were similar between the treatment and placebo intervention periods
(98% of capsules provided were effectively taken in both groups). Baseline values of the
study’s primary outcome variables did not differ signiﬁcantly from those observed after
each washout period, implying that no carryover effects between both interventions
were to be expected.
Daily administration of B. pullicaecorum capsules for 4 weeks was well tolerated by
all participants. No severe adverse events (SAEs) were reported, and the numbers of
reported adverse events (AEs) did not differ signiﬁcantly between the treatment and
placebo periods (Table 2). Participants maintained their normal bowel habits (stool
frequency and consistency and occurrence of abdominal pain, bloating, or other
abdominal pain) during the B. pullicaecorum intervention (Table 2). Changes in fecal
calprotectin levels upon treatment did not differ from those observed over the placebo
intervention, indicating that B. pullicaecorum administration did not elicit intestinal
inﬂammation: the median was 1.1 g/g (interquartile range [IQR], 4.3 to 14.4 g/g)
versus 8.5 g/g (IQR, 6.7 to 46.5 g/g) (P 0.264). Finally, no alterations in variation of
TABLE 1 Baseline characteristics of the study population according to randomization group
Characteristic
Result for:
P valueProbiotic-placebo group Placebo-probiotic group
Sex, no. male/female 7/8 7/8 1.000
Age, yr (range) 32 (26–45) 28 (25–33) 0.176
BMI, kg/m² 23.6  2.1 22.1  1.9 0.064
Smoking status, no. yes/no/ex-smoker 1/13/1 1/10/4 0.314
Medication intake, no. yes/noa 7/8 6/9 0.712
Smoking pack years 0 (0–0) 0 (0–0.5) 0.288
aIntake of medication known to affect microbiota composition or gastrointestinal transit time (including antibiotics, prebiotics, and other probiotics) the preceding
month or during the study was part of the exclusion criteria.
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blood chemistry parameters encompassing hematology values, liver and kidney func-
tion, blood minerals, and lipids were observed when comparing placebo and treatment
interventions (see Table S1 in the supplemental material). The primary endpoints of the
study were thus successfully met.
1 1 2 3 4 1 2 3 1 2 3 4 1 2 3
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Responded to the advertisement
n=145
Received oral explanation
n=36
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n=30
Allocated to Probiotic - Placebo
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n=15
Completed study
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FIG 1 Study design. (A) Schematic representation of the study design. Stool diaries and samples were collected as
depicted. V1 to V7 represent study visits before, during, and after each intervention and/or washout period. (B)
Participant ﬂow diagram showing the number of participants at each stage and reason for dropping out.
TABLE 2 Occurrence of adverse events during the probiotic and placebo intervention
perioda
Symptom Severity
No. of events occurring during
administration of:
P valueProbiotic (n  28) Placebo (n  28)
Abdominal pain Mild 1 1 0.157
Moderate 0 1
Allergic reaction Mild 0 1 1.000
Arthralgia Mild 1 0 1.000
Diarrhea Mild 1 3 0.577
Moderate 1 1
Gastritis and enterocolitis Moderate 1 1 1.000
GI disorders—other, loose stools Mild 4 5 1.000
Laryngeal inﬂammation Moderate 0 1 1.000
Myositis Mild 0 1 1.000
Toothache Mild 0 1 1.000
aValues were compared with McNemar tests when only one grade of severity was reported (mild or moderate)
and with Wilcoxon signed-rank tests when two grades were reported. GI, gastrointestinal; n, number of subjects.
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Butyricicoccus pullicaecorum administration does not disrupt microbial com-
munity structure. Next, we assessed the potential impact of B. pullicaecorum admin-
istration on the health-associated microbiota community structure as reﬂected in fecal
material from healthy volunteers. The microbiome composition of 188 out of 196 fecal
samples collected during the intervention trial fell within the ranges of normal variation
as observed within the Flemish Gut Flora Project data set (24) (8 samples had a read
count of 10,000 and were excluded from analyses) (Fig. 2A). To quantify the effect of
B. pullicaecorum supplementation on community structure, we compared microbiome
dissimilarities (beta-diversity, expressed as Bray-Curtis dissimilarity index) between the
start and the end of each intervention period. We could not observe any difference
between the impact of probiotic treatment and placebo (Wilcoxon signed-rank test, r
0.01, P 0.94). Likewise, compared to placebo, the probiotic did not affect commu-
nity stability, as reﬂected by microbiome richness (Chao1, r0.05, P 0.747 [Fig. 2B])
or evenness (Pielou, r  0.16, P 0.250). B. pullicaecorum administration did not
cause any signiﬁcant changes in abundances of single genera (see Table S2 in the
supplemental material). Of note, no accumulation of the treatment genus over the
intervention study was observed (r  0.12, P  0.363 [Fig. 2B]), indicating transient
colonization of the ecosystem. Overall, we can state that the B. pullicaecorum formu-
lation administered was well tolerated both by the healthy human participants and by
their health-associated intestinal microbiota.
Fecal metabolite proﬁles remain stable throughout Butyricicoccus pullicaeco-
rum intervention. As compositional microbiome stability does not necessarily exclude
ﬂuctuations in microbiota metabolic activity, we assessed the impact of the B. pullicae-
corum intervention on fecal metabolite proﬁles. In total, we relatively quantiﬁed 314
volatile organic compounds (VOCs) in 140 samples (study visits V1, V3, V4, V6, and V7)
from 28 study volunteers, with an average of 88 VOCs per sample. Nineteen VOCs were
detected in all samples, 55 occurred in 80% of the fecal aliquots analyzed, and 64
were characterized as sample speciﬁc. Changes induced in the number of VOCs
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FIG 2 (A) Principal-coordinate analysis (PCoA) of interindividual differences in microbiota composition (Bray-Curtis dissimilarity) with samples included in the
analysis (n  188) and 1,106 samples from the Flemish Gut Flora Project. Samples collected during the intervention trial fell within ranges of normal variation,
and no separation was observed after intervention compared to baseline. (B) Variation in microbiota richness (Chao1) and in relative abundances of the genus
Butyricicoccus after probiotic administration compared to placebo. No signiﬁcant differences were observed (r  0.05 and P 0.747 and r  0.12 and
P  0.363, respectively).
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detected per sample by treatment did not differ from those observed upon placebo
intervention (1.2 9.5 versus 3.1 8.5; P 0.101). Metabolite proﬁles of samples
collected before and after B. pullicaecorum or placebo intervention could not be
discriminated (partial least-squares discriminant analysis [PLS-DA]) (Fig. 3). Accordingly,
probiotic treatment did not lead to signiﬁcant shifts in metabolite relative concentra-
tions compared to placebo and baseline samples (redundancy analysis [RDA],
P 0.468).
To investigate the potential impact of B. pullicaecorum administration on gut
saccharolytic and proteolytic fermentation processes, absolute quantiﬁcation of a
number of selected marker metabolites was performed. The short-chain fatty acids
(SCFAs) acetate, propionate, and butyrate were included as indicators of saccharolytic
fermentation, while dimethyl sulﬁde, p-cresol, indole, and the branched-chain fatty
acids (BCFAs) isobutyrate and isovalerate reﬂect proteolytic metabolism (25). Probiotic-
induced variation in selected marker metabolite concentrations did not differ signiﬁ-
cantly from ﬂuctuations observed over placebo intervention (Table 3). Of note, also
fecal butyrate was not differentially affected by B. pullicaecorum and placebo interven-
PC1
PC
2
−0.2 −0.1 0.0 0.1 0.2 0.3 0.4 0.5
−0.4
−0.3
−0.2
−0.1
0.0
0.1
Samples
Before probiotic
After probiotic
Before placebo
After placebo
FIG 3 Fecal metabolite proﬁle analyzed by PLS-DA. No signiﬁcant difference is found between metabo-
lomes after probiotic intervention compared to baseline (P 0.05 by RDA).
TABLE 3 Probiotic and placebo effects on absolutely quantiﬁed colonic fermentation metabolites after 4 weeks of intake
Metabolite
Chemical
classa
Metabolite concentration withb:
P value for
probiotic vs
placebo
Probiotic Placebo
Start End Start End
Acetate (mM) SCFA 162.14  75.53 176.14  81.55 181.68  80.74 192.28  85.31 0.869
Propionate (mM) SCFA 42.49  27.53 38.86  17.21 40.33  21.29 41.20  17.85 0.436
Butyrate (mM) SCFA 28.31  15.29 29.90  15.42 30.12  15.85 34.09  19.13 0.613
Isobutyrate (mM) BCFA 3.15  1.29 3.57  1.71 3.15  1.35 3.46  1.57 0.815
Isovalerate (mM) BCFA 1.94  0.79 2.37  1.19 2.07  0.96 2.26  1.20 0.457
Dimethyl
sulﬁde (M)
S-compound 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.855
p-Cresol (mM) Phenol 0.61  0.39 0.73  0.49 0.68  0.56 0.69  0.58 0.498
Indole (M) Indole 2.79E3 (1.20E4
to 8.76E3)
1.93E3 (0 to
8.02E3)
1.98E3 (9.32E4
to 4.61E3)
3.09E3 (1.38E3
to 6.43E3)
0.81
aSCFA, short-chain fatty acid; BCFA, branched-chain fatty acid.
bExcept as noted, values are expressed as mean  SD and were compared with paired two-sample t tests when the normality assumption was met. If not, data are
represented as median with IQR in parentheses and were compared with Wilcoxon signed-rank tests.
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tion (two-sample t test, P 0.613). Overall, we can conclude that B. pullicaecorum
consumption did not signiﬁcantly alter microbial metabolite proﬁles as observed in
fecal material from healthy individuals.
DISCUSSION
Advances in gut microbiota research have revived interests in developing novel
probiotic applications. While preclinical evidence in vitro or in animal models has been
shown for several of such next-generation probiotics, few have been tested in humans
(10). These include Clostridium butyricum MIYAIRI 588 (Clostridium cluster I), demon-
strated as safe in vitro and in rodents (26) and moderately effective in treating
Helicobacter pylori infections (27), antibiotic-associated diarrhea (28), and preventing
formation of postsurgery pouchitis in ulcerative colitis patients (29), and Bacteroides
xylanisolvens DSM 23694, which induced generation of antibodies against the cancer-
speciﬁc antigen TF (30). Given the reported anti-inﬂammatory properties of butyrate
(13) and the decreased abundances of butyrate-producing bacteria observed in IBD
patients (15, 16), colon butyrate producers are particularly promising as niche-speciﬁc
next-generation probiotics. Administration of probiotic colon butyrate producers could
potentially exert beneﬁcial effects in patients, reducing intestinal inﬂammation and
restoring eubiosis. B. pullicaecorum 25-3T has been demonstrated to be safe in in vitro
as well as animal models (20). The strain is intrinsically tolerant to the harsh conditions
of the stomach (low pH) and the small intestine (presence of bile salts and pancreatic
enzymes), indicating the potential to reach the colon in a viable and metabolically
active state (21). In addition, the supernatant of the cultured strain also reduced
inﬂammation and prevented epithelial integrity loss in human cell lines (31). However,
production and conservation of strictly anaerobic probiotic bacteria for human con-
sumption remain challenging. Here, we ﬁrst cultured B. pullicaecorum 25-3T, followed
by encapsulation (108 CFU) and pH-resistant coating. Eight months after production (4
months after completion of the study), viability remained at 67%, indicating stability
and an acceptable shelf life of the probiotic formulation (32).
Next, we performed a randomized, double-blind, placebo-controlled crossover trial
with 30 healthy volunteers. Very high compliance rates were attained (98% of the
capsules provided were effectively taken), and no carryover effects were detected. The
primary endpoints of the study were achieved, with daily administration of B. pullicae-
corum being safe and well tolerated, as determined by the absence of differences
between the probiotic and placebo interventions in the occurrence of (severe) adverse
events, blood chemistry parameters, changes in bowel habits, and intestinal inﬂamma-
tion markers. While we would envisage reduced intestinal inﬂammation in patients with
gastrointestinal inﬂammation, no changes were expected in the present safety trial
with healthy individuals.
Secondary endpoints of the study included effects of the probiotic formulation on
microbiota composition and metabolic activity. B. pullicaecorum administration did not
disrupt microbial community structure, and no alterations in relative abundances of
speciﬁc microbial taxa were detected. Furthermore, there was no accumulation of
Butyricicoccus sequences over the intervention, and thus, we can conclude that the
probiotic did not persist in the colon of the study participants. The microbial metabolic
activity also remained stable throughout the intervention. No signiﬁcant increase in
fecal butyrate levels measured was detected after probiotic compared to placebo
intervention. While we cannot rule out this being a consequence of the probiotic
dosage used in the study, fecal measurements have been challenged as a readout of
colonic microbial butyrate production. As up to 95% of SCFAs are estimated to be
rapidly absorbed by colonocytes, the fraction excreted in feces only reﬂects the ratio
between production and absorption rates and not the in situ production of the
metabolites (26).
In conclusion, this randomized placebo-controlled crossover study demonstrated
safety of B. pullicaecorum 25-3T administration to healthy subjects. The strain is not only
well tolerated by the human host, but also does not cause any disruptive changes in
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the composition or metabolic activity of a health-associated gut microbiota. Hence, as
a further step in the development of B. pullicaecorum as a next-generation probiotic, an
intervention study using a therapeutic dosage of the strain grown in an adjusted,
food-grade culture medium in a clinical setting can be envisaged to study the strain’s
effect on disease-associated microbiota alterations and the accompanying impact on
host health and well-being.
MATERIALS AND METHODS
Study design. (i) Study population. Thirty healthy subjects were recruited among students of the
KU Leuven and employees of the University Hospital of Leuven. All subjects were generally healthy, had
a regular eating pattern, were free of medication affecting intestinal transit or gut microbiota, and did
not take any pre-, pro-, or antibiotics during the month preceding the study. None of the subjects had
a history of gastrointestinal (GI) disease (IBD, IBS [irritable bowel syndrome], or diarrhea) or abdominal
surgery (with the exception of appendectomy). Additional exclusion criteria were following a weight loss
diet during the month preceding the study, maintaining strict dietary habits (e.g., veganism), pregnancy
or breastfeeding, and intake of more than 10 alcoholic drinks per week. Subjects were instructed to
maintain their usual diet during the study period and to avoid any intake of pre- and other probiotics.
The study was approved by the Ethics Committee of the University Hospitals Leuven (ML9449). All
subjects gave their written informed consent prior to enrollment. The trial was registered at ClinicalTri-
als.gov (NCT02477033).
(ii) Study product. The bacterial strain Butyricicoccus pullicaecorum 25-3T (LMG 24109T; CCUG
55265T) was cultured in M2GSC broth at pH 6 for 24 h at 37°C under anaerobic conditions (84% N2, 8%
CO2, 8% H2) as described by Miyazaki et al. (27), with the addition of 15% (vol/vol) clariﬁed rumen ﬂuid
instead of 30%. After overnight incubation, bacteria were collected by centrifugation (10 min, 5,000  g,
37°C), resuspended in a lyoprotectant (consisting of horse serum supplemented with 7.5% trehalose and
1 mg/ml cysteine-HCl, pH 6). All manipulations were performed under anaerobic conditions (84% N2, 8%
CO2, 8% H2). The suspensions were freeze-dried overnight using an Alpha 1-2 LDplus (Christ, Osterode,
Germany) freeze drier under default operation conditions. Cultivability of the strain was determined
through anaerobic plating of serial dilutions on M2GSC agar (16). Hydroxypropyl methylcellulose (HPMC)
size 0 capsules were manually ﬁlled with 400 mg lyophilized product at a concentration of 108 CFU/
capsule. The capsules were sealed and coated with a pH-resistant coating consisting of the enteric
polymer cellulose acetate phthalate (CAP) and the plasticizer diethyl phthalate by SEPS Pharma NV
(Ghent, Belgium). Placebo capsules were ﬁlled with maltodextrin (Paselli MD 6; Avebe, Veendam, The
Netherlands) and coated as described above. All capsules were stored in heat-sealed aluminum sachets
at 4°C. Eight months after capsule production, bacterial viability was determined as a measure for
product stability.
(iii) Study setup. The study was set up as a randomized, double-blind, placebo-controlled crossover
trial, conducted between February and June 2014. Study design included a 1-week run-in period and two
interventions of 4 weeks, each followed by a washout of 3 weeks (Fig. 1). Volunteers were randomly
allocated to one of the randomization groups at a 1:1 ratio, starting with either the probiotic or placebo
intervention period. Block randomization of the subjects was performed by an independent researcher
who was not involved in the study using an online randomization tool (www.randomization.com) with
a ﬁxed block size of four, stratiﬁed for sex and visit sequence. Probiotic and placebo capsules were sealed
in identical containers and appointed to the subjects by the independent researcher. Subjects as well as
the study researchers were blind to the intervention sequence until termination of all analytical
assessments. During the run-in week, study volunteers were asked to ﬁll in a defecation journal and GI
questionnaire. After the run-in period, participants visited the lab to provide a fasted blood sample and
to deposit a fecal sample collected in the 24 h preceding the visit and stored intermediately at 4°C.
During the ﬁrst intervention period, subjects consumed daily one capsule containing the bacterial strain
(108 CFU [treatment intervention]) or maltodextrin (placebo intervention) at breakfast for 4 weeks. After
a washout period of 3 weeks, subjects switched to the alternative intervention again for 4 weeks,
followed by a ﬁnal 3-week washout. Fecal and blood samples were collected after weeks 2 and 4 of the
intervention periods and at the end of each washout period. During the week preceding sampling,
participants kept a defecation journal and completed a GI questionnaire. At each lab visit, subjects were
asked to report changes in medication and the occurrence of adverse events during the preceding
period. Adverse events were categorized and graded on their severity according to the Common
Terminology Criteria for Adverse Events version 4 (28). Participants were instructed to return the
remaining capsules after each intervention period to check compliance.
(iv) Study endpoints. The primary endpoint of the trial was the assessment of safety and tolerability
of B. pullicaecorum administration in healthy subjects. To do so, GI complaints, stool parameters, blood
parameters, and fecal calprotectin concentrations were determined. As secondary outcome variables, the
impact of the bacterial strain on microbial composition and activity was assessed.
Analytical methods. (i) Defecation journals. Defecation journals contained daily information on
stool frequency, stool consistency (Bristol stool score), and GI symptoms, such as abdominal pain and
bloating. Parameters were averaged per week to obtain one value per parameter for each study visit.
Additionally, participants reported symptom scores at the end of each week based on overall abdominal
pain, bloating, defecation and stool speciﬁcations, and abdominal complaints during that week.
(ii) Blood parameters. Hematological parameters, liver and kidney function parameters, and blood
lipids and minerals were quantiﬁed using standard laboratory techniques.
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(iii) Fecal calprotectin. To measure fecal calprotectin, a marker of intestinal inﬂammation, stool
aliquots were extracted using the Smart-Prep fecal sample preparation kit (Bühlmann Laboratories AG,
Schönenbuch, Switzerland), and extracts were kept at 20°C. Afterwards, fecal calprotectin was quan-
tiﬁed using a sandwich immunoassay (Quantum Blue quantitative calprotectin lateral ﬂow assay;
Bühlmann Laboratories AG) following the manufacturer’s instructions. Calprotectin concentrations were
expressed in g/g stool.
(iv) Gut microbiota composition. Microbial DNA was extracted from frozen fecal samples using the
PowerMicrobiome RNA isolation kit (Mo Bio Laboratories, Inc., Carlsbad, CA) as described previously (24).
16S rRNA genes were ampliﬁed using the 515F/806R primer set, targeting the V4 hypervariable region
(29). Sequencing was performed using the Illumina MiSeq platform with sequencing kit MiSeq v2,
producing 250-bp paired-end reads. For sequence analysis, fastq sequences were merged using FLASH
version 1.2.10 (30) and quality ﬁltered (threshold: 90% of nucleotides should have a quality score of
25) with the FASTX-Toolkit v0.0.14 (http://hannonlab.cshl.edu/fastx_toolkit/). Chimera removal was
performed using the UCHIME algorithm in USEARCH v6.0.307 (31), and taxonomical assignment of
sequences was performed with the RDP classiﬁer v2.12 (32). Phylum-to-genus matrices were subse-
quently created using Perl scripts. Samples were rareﬁed to 10,000 randomly selected reads, with
samples with 10,000 reads (n  8) excluded from the analysis.
(v) Fecal metabolite proﬁles. Fecal aliquots of 125 mg were suspended in a total volume of 5 ml
H2O, together with a pinch of Na2SO4 (99%; Acros, Geel, Belgium) to salt out the solution, 130 l of H2SO4
(98%; Merck, Darmstadt, Germany) for acidiﬁcation, a magnetic stirrer, and 20 l of internal standard
(2-ethyl butyrate [1.6 mg/liter, 99%; Merck], diethyl sulﬁde [0.047 mg/liter, 98%; Sigma-Aldrich, Steinheim,
Germany], and 2,6-dimethyl phenol [0.162 mg/liter, 99.5%; Sigma-Aldrich]). Volatile organic compounds
(VOCs) were analyzed using a gas chromatography-mass spectrometry (GC-MS) quadrupole system
(Trace GC Ultra and DSQ II; Thermo Electron Corporation, Waltham, MA), coupled on-line to a purge-
and-trap system (Velocity; Teldyne Tekmar, Mason, OH), as previously described (33). The VOCs were
separated on an analytical column (AT Aquawax DA, 30 m by 0.25-mm inside diameter [i.d.], 0.25-m ﬁlm
thickness; Grace, Deerﬁeld, IL), and masses were detected betweenm/z 33 and 200 at 1.5 full scans/s. The
resulting chromatograms were processed using AMDIS (Automatic Mass Spectral Deconvolution and
Identiﬁcation Software version 2.71) provided by the National Institute of Standards and Technology
(NIST). This software uses adjacent peak deconvolution and background subtraction to acquire clariﬁed
spectra from the overlapping peaks. The mass spectra of unknown peaks were then compared to the
NIST library and were positively identiﬁed when having a match factor of 90%. Relative indices (RIs) of
all VOCs were calculated versus 2-ethyl butyrate as an internal standard, and VOCs were classiﬁed
according to chemical class. The resulting metabolite proﬁles were organized in a three-dimensional data
matrix using sample names (observations), identiﬁed metabolites (variables), and normalized peak
intensity versus 2-ethyl butyrate (variable indices). A number of metabolites were selected as markers for
saccharolytic fermentation (the short-chain fatty acids [SCFAs] acetic acid, propionic acid, and butyric
acid) and proteolytic fermentation (dimethyl sulﬁde, p-cresol, indole, and the branched-chain fatty acids
[BCFAs] isobutyric acid and isovaleric acid). They were absolutely quantiﬁed using appropriate calibration
curves obtained with internal standard quantiﬁcation. SCFAs and BCFAs were quantiﬁed using 2-ethyl
butyrate as the corresponding internal standard, whereas p-cresol and indole were quantiﬁed versus
2,6-dimethyl phenol and dimethyl sulﬁde versus diethyl sulﬁde.
Statistical analysis. (i) Study population characteristics. Differences between the visit after an
intervention period and that preceding this period were calculated to compare effects of the interven-
tions (probiotic effect and placebo effect). Assumptions of normality were explored using the Shapiro-
Wilk test. When the assumption was met, differences were evaluated using paired two-sample t tests, and
values were expressed as mean  standard deviation (SD). When the normality assumption was not met
or when the data were ordinal, Wilcoxon signed-rank tests were performed and data were presented as
median with interquartile range (IQR) in parentheses. Similarly, when data comparisons were unpaired,
unpaired two-sample t tests and Mann-Whitney U tests were used, respectively. Binary data were
compared using the Pearson chi-square test when unpaired and with the McNemar test in the case of
paired data. For nominal data, the likelihood-ratio chi-square test was applied. Results were corrected for
multiple testing using the Benjamini and Hochberg false-discovery rate (FDR) correction (27). Statistical
analyses were performed using the R statistical software (34). The level of statistical signiﬁcance was set
at P 0.05, with P 0.1 considered a trend toward signiﬁcance.
(ii) Microbiota composition. Statistical analysis of microbiota composition and graphical represen-
tations were performed in R (version 3.4.3), using the packages vegan (35), phyloseq (36), coin (37), and
ggplot2 (38). Beta-diversity (Bray-Curtis dissimilarity index) and alpha-diversity, including richness (ob-
served) and evenness (Pielou’s index), were calculated using the vegan R package on genus-level relative
abundance matrices. Intervention-associated variations in relative abundances of microbial taxa were
assessed in genera present in at least 15% of the samples and with a mean relative abundance of1e4.
The inﬂuence of probiotic intervention on microbial diversity indices and taxa compared to placebo
(difference between samples before and after intervention) was assessed with Wilcoxon signed-rank
tests. Correction for multiple testing (Benjamini-Hochberg procedure, FDR) was applied, and signiﬁcance
was deﬁned at an FDR of10%.
(iii) Metabolite proﬁles. Sample-speciﬁc metabolites were removed from the analysis as they do not
exert any discriminatory power (39). Principal-component analysis (PCA) was applied to detect outliers
(n  3), which were excluded from further analysis. Partial least-squares discriminant analysis (PLS-DA)
with full cross-validation was performed with the mdatools R package (40) to cluster samples with similar
metabolite proﬁles according to the intervention, and the result was presented as a score plot.
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Corresponding loading plots showing the metabolites were used to identify components accounting for
that discrimination. The inﬂuence of probiotic treatment on metabolite proﬁles was determined by
redundancy analysis (RDA) using the vegan R package (35).
Data availability. Data have been made available at the European Nucleotide Archive under
accession no. PRJEB29261.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSystems.00094-18.
TABLE S1, PDF ﬁle, 0.1 MB.
TABLE S2, PDF ﬁle, 0.1 MB.
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